Back to Search
DIEGO CARRERA, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1932769031Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (17)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
PMID 18669875·Blood·2008
3-trial
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
PMID 19001321·J Clin Oncol·2008
4-observational
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
PMID 18612103·Blood·2008
3-trial
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
PMID 18322252·Haematologica·2008
3-trial
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
PMID 18086801·J Clin Oncol·2008
4-observational
Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
PMID 17378891·Eur J Haematol·2007
8-other
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
PMID 17024116·Leukemia·2007
3-trial
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
PMID 16772605·Blood·2006
3-trial
Patients with learning difficulties: outcome on peritoneal dialysis.
PMID 16983953·Adv Perit Dial·2006
8-other
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
PMID 16627253·Haematologica·2006
3-trial
Neuropharmacological profile of an ethanol extract of Ruta chalepensis L. in mice.
PMID 16442764·J Ethnopharmacol·2006
7-preclinical
Subdermal re-injection: a method to increase surgical detection of the sentinel node in breast cancer without increasing the false-negative rate.
PMID 16307292·Eur J Nucl Med Mol Imaging·2006
4-observational
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.
PMID 15737986·Ann Oncol·2005
4-observational
Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome.
PMID 12702529·Ann Oncol·2003
8-other
Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.
PMID 11230484·J Clin Oncol·2001
4-observational
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
PMID 11920166·Hematol J·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- MSC 10-5615, I UNIVERSITY OF NEW MEXICO
ALBUQUERQUE, NM 87131 - Phone
- (505) 272-3160
Quick Facts
- NPI
- 1932769031
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 17
Are you this provider?
Claim Your Profile